What endocrinology is researching now
The topics gaining the most ground, ranked by the PubDaily Trend Score: new research, stronger evidence, new trials and new guidelines. 291 topics in 22 specialties, updated 18 Oct 2026.
Monthly reportThe fastest-rising topics in medicine: October 2026Read →Tirzepatide
A dual GIP/GLP-1 receptor agonist for diabetes and obesity.
Next-generation incretin drugs
Triple agonists and amylin combinations such as retatrutide and CagriSema.
Key point: CagriSema led to a greater proportion of adults with obesity achieving BMI and waist-to-height ratio targets than semaglutide, cagrilintide, or placebo.
Oral GLP-1 drugs
Oral semaglutide and small-molecule GLP-1 agonists such as orforglipron.
Key point: In adults with obesity or overweight and type 2 diabetes, once-daily orforglipron reduced bodyweight versus placebo, with safety similar to other GLP-1 agonists.
Automated insulin delivery
Hybrid closed-loop systems that adjust insulin automatically.
Primary aldosteronism
Screening, diagnosis and treatment of primary aldosteronism.
Key point: Universal screening for primary aldosteronism in all patients with hypertension with an aldosterone-to-renin ratio test is now recommended.
Menopausal hormone therapy
Hormone therapy for menopausal symptoms, benefits and risks.
See all 12 endocrinology topics
Every rising topic, with the papers behind it. Free for doctors.
How the Trend Score works
Four signals
Growth in new papers (35%), growth in randomised trials, meta-analyses and systematic reviews (25%), new clinical trials registered (20%), and new guidelines and consensus statements (20%), each over the last 12 months against the 12 before.
A score out of 100
Each signal is ranked against every topic we follow, so a score of 90 means the topic is ahead of about 90% of them. Rising fast: 80 and above. Rising: 55 to 79. Emerging: fewer than 100 papers the year before, too few to rank.
What it does not tell you
More research on a topic is not evidence that a treatment works. Open a topic to read the papers and guidelines themselves. Counts come from PubMed and ClinicalTrials.gov.